Related Experiment Video
Updated: Mar 7, 2026
Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
Antitumor activity of interferon-β1a in hormone refractory prostate cancer with neuroendocrine differentiation
A Dicitore1, E S Grassi2, M O Borghi2,3
1Laboratory of Endocrine and Metabolic Research, Istituto Auxologico Italiano IRCCS, via Zucchi 18, Cusano Milanino (Mi), 20095, Milan, Italy.
Purpose:
Type I interferons (IFN-α and IFN-β) are a class of cytokines that exert several biological activities, such as modulation of cell proliferation and differentiation and of the immune system. Although these cytokines interact with a common receptor complex, IFN-β showed a more potent antitumor activity than IFN-α in several tumor models. New recombinant human IFN-β products, such as IFN-β1a and IFN-β1b, have been produced in order to improve the stability and bioavailability of natural IFN-β. In this report, we analyzed the effects of recombinant IFN-β1a on the cell proliferation of two human androgen-resistant prostate cancer cell lines with neuroendocrine differentiation (DU-145, PC-3) and related mechanisms of action.
Methods:
The effects of IFN-β1a on the cell growth proliferation, cell cycle, and apoptosis have been evaluated in DU-145 and PC-3 cells through MTT assay, DNA flow cytometry with propidium iodide, and Annexin V-FITC/propidium iodide staining, respectively. Moreover, the expression of neuron-specific enolase (NSE), cleaved caspase-3, caspase-8, and PARP was evaluated through Western blotting.
Results:
IFN-β1a showed a significant anti-proliferative activity in both androgen-resistant cell lines. This effect was related to cell cycle perturbation and induction in apoptosis, as shown by flow cytometric analysis, the activation of caspase-3 and caspase-8 and PARP cleavage during incubation with IFN-β1a. Moreover, this cytokine reduced the expression of NSE in both cell lines.
Conclusions:
Recombinant IFN-β1a (Rebif) showed a potent in vitro anti-proliferative activity in androgen-resistant prostate cancer cells, and it could represent a promising tool for the treatment of this tumor.
Insights
Recombinant interferon-beta 1a (IFN-β1a) effectively inhibits prostate cancer cell growth by inducing apoptosis and cell cycle arrest. This cytokine also reduces neuroendocrine differentiation markers in androgen-resistant prostate cancer models.
Area of Science:
- Oncology
- Immunology
- Cell Biology
Background:
- Type I interferons (IFN-α, IFN-β) modulate cell proliferation and immunity.
- IFN-β exhibits greater antitumor activity than IFN-α.
- Recombinant IFN-β1a and IFN-β1b enhance stability and bioavailability.
Purpose of the Study:
- Analyze recombinant IFN-β1a effects on androgen-resistant prostate cancer cell lines (DU-145, PC-3).
- Investigate mechanisms of action, including cell proliferation and neuroendocrine differentiation.
Main Methods:
- MTT assay for cell proliferation.
- Flow cytometry for cell cycle and apoptosis analysis.
- Western blotting for protein expression (NSE, caspases, PARP).
Main Results:
- IFN-β1a demonstrated significant anti-proliferative activity in both cell lines.
- Apoptosis induction and cell cycle perturbation were observed.
- Reduced neuron-specific enolase (NSE) expression and activated caspases/PARP confirmed efficacy.
Conclusions:
- Recombinant IFN-β1a exhibits potent in vitro anti-proliferative activity against androgen-resistant prostate cancer.
- IFN-β1a shows promise as a therapeutic agent for prostate cancer treatment.
